Publications by authors named "Jacob D Bitran"

Claim this Profile
A
A phase 1/2 study of ixazomib in place of bortezomib or carfilzomib in a subsequent line of therapy for patients with multiple myeloma refractory to their last bortezomib or carfilzomib combination regimen.
David Daniely, Eli Forouzan, Tanya M Spektor, Alexa Cohen, Jacob D Bitran

Exp Hematol· July 2022

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Reducing Unwarranted Oncology Care Variation Across a Clinically Integrated Network: A Collaborative Physician Engagement Strategy.
Jon M Richards, Trever B Burgon, Diana Tamondong-Lachica, Jacob D Bitran, Wilfredo L Liangco

J Oncol Pract· December 2019

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety of BTZ retreatment for patients with low-grade peripheral neuropathy during the initial treatment.
Aleksandra P Vidisheva, James Wang, Tanya M Spektor, Jacob D Bitran, Jose Lutzky

Support Care Cancer· October 2017

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
R
Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.
Andrew Meyer, Peter Cygan, Kathy Tolzien, Angel G Galvez, Jacob D Bitran

Clin Genitourin Cancer· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy.
Chadi Nabhan, Andrew Meyer, Kathy Tolzien, Jacob D Bitran, Timothy M Lestingi

Avicenna J Med· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Efficacy and safety of clofarabine in relapsed and/or refractory non-Hodgkin lymphoma, including rituximab-refractory patients.
Chadi Nabhan, Nancy Davis, Jacob D Bitran, Angel Galvez, Walter Fried

Cancer· April 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
D
Disclosing the cancer diagnosis:the myth and the truth.
Chadi Nabhan, Jacob D Bitran, Clint Moore

J Clin Oncol· February 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A comparison of HLA-identical sibling allogeneic versus autologous transplantation for diffuse large B cell lymphoma: a report from the CIBMTR.
Hillard M Lazarus, Mei-Jie Zhang, Jeanette Carreras, Brandon M Hayes-Lattin, Asli Selmin Ataergin, Jacob D Bitran

Biol Blood Marrow Transplant· January 2010

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.
Chadi Nabhan, Timothy M Lestingi, Angel Galvez, Kathy Tolzien, Susan K Kelby, Jacob D Bitran

Urology· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
I
Influence of age and histology on outcome in adult non-Hodgkin lymphoma patients undergoing autologous hematopoietic cell transplantation (HCT): a report from the Center For International Blood & Marrow Transplant Research (CIBMTR).
Hillard M Lazarus, Jeanette Carreras, Christian Boudreau, Fausto R Loberiza, James O Armitage, Jacob D Bitran

Biol Blood Marrow Transplant· December 2008

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
M
Mitomycin-C/5-fluorouracil/leucovorin and hyperfractionated radiation therapy for rectal carcinoma: a phase II study with long-term follow-up.
Chadi Nabhan, Avanthi Ragam, Brian Samuels, Daniel T Milton, Leela Prasad, Jacob D Bitran

Clin Colorectal Cancer· March 2007

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase I evaluation of oral CI-1033 in combination with paclitaxel and carboplatin as first-line chemotherapy in patients with advanced non-small cell lung cancer.
Alberto A Chiappori, Peter M Ellis, John Turner Hamm, Jacob David Bitran, Irene Eiseman

J Thorac Oncol· November 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
T
Thalidomide and dexamethasone for newly diagnosed multiple myeloma: is this really the standard of care?
Chadi Nabhan, Jacob D Bitran

J Clin Oncol· June 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
P
Phase II study of PKC-alpha antisense oligonucleotide aprinocarsen in combination with gemcitabine and carboplatin in patients with advanced non-small cell lung cancer.
Paul Ritch, Charles M Rudin, Jacob David Bitran, Martin J Edelman, Alex Makalinao

Lung Cancer· May 2006

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Chronic lymphocytic leukemia: to transplant or not to transplant... that is the question?
Chadi Nabhan, Jacob D Bitran

J Clin Oncol· November 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erlotinib in lung cancer.
Chadi Nabhan, Jacob D Bitran

N Engl J Med· October 2005

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
H
High-dose myeloablative therapy and autologous peripheral blood progenitor cell transplantation for elderly patients (greater than 65 years of age) with relapsed large cell lymphoma.
Jacob D Bitran, Leonard Klein, Doreen Link, Jane Kosirog-Glowacki, Cynthia Stewart

Biol Blood Marrow Transplant· June 2003

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis